{
    "ids": [
        [
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-ARTICLE VIII TERMINATION, AMENDMENT AND WAIVER-48",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Notice of Termination\u037e Effect of Termination-50",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Termination-49",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Termination-18",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Termination Fee\u037e Certain Expenses-19",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Severability-55",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Fees and Expenses-51",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Entire Agreement-54",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Survival of Representations, Warranties and Covenants-52",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Remedies-56"
        ],
        [
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Solicitation of Proxies-2",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-ANNEX C\u2014OPINION OF GOLDMAN SACHS & CO. LLC-23",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-ANNEX B\u2014OPINION OF CENTERVIEW PARTNERS LLC-22"
        ],
        [
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Confidentiality-53",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Data Privacy and Security-31",
            "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf-Intellectual Property-30"
        ]
    ],
    "distances": [
        [
            0.3256241977214813,
            0.3332411050796509,
            0.36853137612342834,
            0.3771379888057709,
            0.38622283935546875,
            0.3885593116283417,
            0.3923419117927551,
            0.39302319288253784,
            0.41014939546585083,
            0.41810521483421326
        ],
        [
            0.47582685947418213,
            0.4890352189540863,
            0.5123035907745361
        ],
        [
            0.3545464277267456,
            0.4100708067417145,
            0.4447517991065979
        ]
    ],
    "metadatas": [
        [
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 183,
                "Keyword": "Termination",
                "Section Header": "ARTICLE VIII TERMINATION, AMENDMENT AND WAIVER",
                "Start Page": 183
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 184,
                "Keyword": "Termination",
                "Section Header": "Notice of Termination\u037e Effect of Termination",
                "Start Page": 184
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 184,
                "Keyword": "Termination",
                "Section Header": "Termination",
                "Start Page": 183
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 110,
                "Keyword": "Termination",
                "Section Header": "Termination",
                "Start Page": 108
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 111,
                "Keyword": "Termination",
                "Section Header": "Termination Fee\u037e Certain Expenses",
                "Start Page": 110
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 189,
                "Keyword": "Termination",
                "Section Header": "Severability",
                "Start Page": 189
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 186,
                "Keyword": "Termination",
                "Section Header": "Fees and Expenses",
                "Start Page": 184
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 188,
                "Keyword": "Termination",
                "Section Header": "Entire Agreement",
                "Start Page": 188
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 187,
                "Keyword": "Termination",
                "Section Header": "Survival of Representations, Warranties and Covenants",
                "Start Page": 187
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 190,
                "Keyword": "Termination",
                "Section Header": "Remedies",
                "Start Page": 189
            }
        ],
        [
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 43,
                "Keyword": "Indemnification",
                "Section Header": "Solicitation of Proxies",
                "Start Page": 43
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 198,
                "Keyword": "Indemnification",
                "Section Header": "ANNEX C\u2014OPINION OF GOLDMAN SACHS & CO. LLC",
                "Start Page": 198
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 198,
                "Keyword": "Indemnification",
                "Section Header": "ANNEX B\u2014OPINION OF CENTERVIEW PARTNERS LLC",
                "Start Page": 195
            }
        ],
        [
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 188,
                "Keyword": "Confidentiality",
                "Section Header": "Confidentiality",
                "Start Page": 188
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 159,
                "Keyword": "Confidentiality",
                "Section Header": "Data Privacy and Security",
                "Start Page": 158
            },
            {
                "Document": "Prometheus Biosciences, Inc._20230516_DEFM14A_20886960_4667711.Pdf",
                "End Page": 158,
                "Keyword": "Confidentiality",
                "Section Header": "Intellectual Property",
                "Start Page": 157
            }
        ]
    ],
    "documents": [
        [
            "ARTICLE VIII\nTERMINATION, AMENDMENT AND WAIVER",
            "8.2 Notice of Termination\u037e Effect of Termination. Any proper and valid termination of this Agreement pursuant to Section 8.1 shall be effective\nimmediately upon the delivery of written notice by the terminating party to the other party or parties hereto, as applicable, specifying the provision or\nprovisions pursuant to which such termination is being effected. In the event of the termination of this Agreement pursuant to Section 8.1, this\nAgreement shall be of no further force or effect and there shall be no liability of any party or parties hereto (or any director, officer, employee, Affiliate,\nagent or other representative of such party or parties) to the other party or parties hereto, as applicable, except (a) the penultimate sentence of Section\n6.6, this Section 8.2, Section 8.3 and Article IX and the terms of the Confidentiality Agreement, each of which shall survive the termination of this\nAgreement, and (b) that nothing herein shall relieve any party or parties hereto, as applicable, from any liability or damage resulting from any fraud or\nWillful Breach of this Agreement that occurs prior to such termination (which liability or damages the parties acknowledge and agree shall not be limited\nto reimbursement of out-of-pocket fees, costs or expenses incurred in connection with the transactions contemplated hereby, and may include, subject to\nthe last sentence of Section 9.6, damages based on loss of the economic benefit of the transactions contemplated by this Agreement to the Company\nStockholders (taking into consideration all relevant matters, including other combination opportunities and the time value of money)). Subject to the last\nsentence of Section 9.6, the parties hereto acknowledge and agree that, to the extent Parent or Merger Sub are required to pay damages in connection\nwith the termination of this Agreement that exceeds the Company\u2019s expenses or out-of-pocket costs incurred in connection with this Agreement and the\ntransactions contemplated hereby, including any disputes related thereto, such excess represents an amount of damages payable in respect of losses\nsuffered by the Persons who are Company Stockholders as of the date on which this Agreement is terminated in respect of Company Shares.\n8.3",
            "8.1 Termination. This Agreement may be terminated and the transactions contemplated hereby may be abandoned at any time prior to the Effective\nTime (it being agreed that the party hereto terminating this Agreement pursuant to this Section 8.1 shall give prompt written notice of such termination to\nthe other party or parties hereto and that any termination by Parent also shall be an effective termination by Merger Sub):\n(a) by mutual written agreement of Parent and the Company\u037e\n(b) by either Parent or the Company:\n(i) if (A) the Effective Time shall not have occurred on or before April 15, 2024 (the \u201cTermination Date\u201d)\u037e provided, however, that the\nright to terminate this Agreement pursuant to either clause (A) or (B) of this Section 8.1(b)(i) shall not be available to any party hereto (which shall\ninclude, in the case of Parent, Parent and Merger Sub) whose breach of its obligations under this Agreement has been a principal cause of the failure of\nthe Effective Time to occur on or before the date of such termination\u037e or\n(ii) if any court of competent jurisdiction or any other Governmental Authority of competent jurisdiction shall have issued any Order,\nor any Law shall be in effect that was enacted, promulgated or deemed applicable to the Merger by any Governmental Authority of competent\njurisdiction, in each case, permanently restraining, enjoining, preventing or otherwise prohibiting or making illegal prior to the Effective Time, the\nconsummation of the Merger, and, in each case, such Order or Law shall have become final and nonappealable\u037e provided, that the right to terminate this\nAgreement pursuant to this Section 8.1(b)(ii) shall be available only if the party (which shall include, in the case of Parent, Parent and Merger Sub)\nseeking to terminate this Agreement pursuant to this Section 8.1(b)(ii) shall have fully complied with its obligations under Section 6.2 and Section 6.3\nprior to asserting the right to terminate arising pursuant to this Section 8.1(b)(ii)\u037e or\n(iii) the Stockholders Meeting shall have been held and the Stockholder Approval shall not have been obtained thereat or at any\nadjournment or postponement thereof\u037e\n(c) by the Company, in the event that:\n(i) (A) the Company is not in breach of this Agreement such that Parent has the right (or would have the right following notice and an\nopportunity to cure, if applicable) to terminate this Agreement pursuant to Section 8.1(d)(i), (B) Parent and/or Merger Sub shall have breached or\notherwise failed to perform any of their respective covenants or agreements, or other obligations under this Agreement, or any of the representations and\nwarranties of Parent and Merger Sub set forth in this Agreement shall have become or been inaccurate, which breach, failure to perform or inaccuracy,\nindividually or in the aggregate with other such breaches, failures to perform or inaccuracies, would reasonably be expected to prevent, materially impede\nor materially delay the ability of Parent or Merger Sub to consummate the transactions contemplated by this Agreement (including the Merger), and (C)\nsuch breach, failure to perform or inaccuracy of Parent and/or Merger Sub is not capable of being cured by the Termination Date or is not cured within\ntwenty (20) Business Days following the Company\u2019s delivery of written notice to Parent of such breach, failure to perform or inaccuracy\u037e or\n(ii) prior to obtaining the Stockholder Approval, if (A) the Company Board (or a committee thereof) shall have determined to terminate\nthis Agreement in accordance with the terms set forth in Section 5.3 (including that the Company has complied in all material respects with Section 5.2\nand Section 5.3 in connection with the relevant Acquisition Proposal) in order to substantially concurrently with such termination enter into a definitive\nagreement with respect to a Superior Proposal, and (B) the Company pays Parent the Company Termination Fee payable to Parent pursuant to Section\n8.3(c)(ii)\u037e\n(d) by Parent in the event that:\n(i) (A) Parent and Merger Sub are not in breach of this Agreement such that the Company has the right (or would have the right\nfollowing notice and an opportunity to cure, if applicable) to terminate this\n \nA-53Table of Contents\nAgreement pursuant to Section 8.1(c), (B) the Company shall have breached or failed to perform any of its covenants or agreements or other obligations\nunder this Agreement that would give rise to the failure of the condition set forth in Section 7.2(b) to be satisfied if such breach or failure to perform were\ncontinuing as of immediately prior to the Effective Time, or any of the representations and warranties of the Company set forth in this Agreement shall\nhave been or becomes inaccurate, such that the condition set forth in Section 7.2(a) is not capable of being satisfied by at the Effective Time, and (C)\nsuch breach, failure to perform or inaccuracy of the Company is not capable of being cured by the Termination Date or is not cured within twenty (20)\nBusiness Days following Parent\u2019s delivery of written notice to the Company of such breach, failure to perform or inaccuracy\u037e or\n(ii) (A) a Company Board Recommendation Change shall have occurred, or (B) a tender or exchange offer constituting an Acquisition\nProposal shall have been publicly commenced by a Person who is not an Affiliate or Representative of Parent and the Company fails to publicly reaffirm\nthe Company Board Recommendation within ten (10) Business Days following the receipt of a written request from Parent to do so.",
            "Termination\nThe Merger Agreement may be terminated and the transactions contemplated thereby may be abandoned, at any time prior to the Effective Time, as\nfollows:\n \n\u2022\nby mutual written agreement of Prometheus and Merck\u037e\n \n98Table of Contents\n\u2022\nby either Prometheus or Merck, if:\n \n\u2022\nthe Effective Time has not occurred on or before the Termination Date, provided that the terminating party\u2019s breach of its obligations\nunder the Merger Agreement may not have been a principal cause of the failure of the Effective Time to occur on or before the\nTermination Date\u037e\n \n\u2022\na court of competent jurisdiction or other governmental authority of competent jurisdiction has issued any order or law permanently\nrestraining, enjoining, preventing, or otherwise prohibiting or making illegal prior to the Effective Time, the consummation of the\ntransactions contemplated by the Merger Agreement that becomes final and non-appealable (except that the party seeking to\nterminate the Merger Agreement as described in this bullet must have used reasonable best efforts to take, or cause to be taken, all\nactions that are necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable, the\nMerger and each of the other transactions contemplated by the Merger Agreement, including to resist, contest, appeal and remove\nany legal proceeding and have vacated, lifted, reversed or overturned any order, whether temporary, preliminary or permanent, that is\nin effect and that prohibits, prevents, restricts or restrains the consummation of the transactions contemplated by the Merger\nAgreement and, if applicable, taking any and all actions as required by the Merger Agreement to obtain antitrust approvals as more\nfully described under \u201cThe Merger Agreement\u2014Other Covenants and Agreements\u2014Efforts to Consummate the Merger\u201d beginning\non page 94 of this proxy statement) prior to asserting the right to terminate arising pursuant to this bullet\u037e or\n \n\u2022\nthe Special Meeting has been held and the Prometheus Stockholder Approval was not obtained at any adjournment or postponement\nthereof\u037e\n \n\u2022\nby Merck, if:\n \n\u2022\nPrometheus breaches or fails to perform any of its covenants or agreements or other obligations set forth in the Merger Agreement,\nwhich breach or failure to perform would cause any of the conditions to Merck\u2019s and Merger Sub\u2019s obligations to consummate the\nMerger not to be satisfied if such breach or failure to perform were continuing as of immediately prior to the Effective Time, or any of\nthe representations and warranties of the Company set forth in the Merger Agreement become inaccurate such that the closing\nconditions with respect to the Company\u2019s representations and warranties are not capable of being satisfied at the Effective Time, and\nsuch breach, failure to perform or inaccuracy is incapable of being cured by the Termination Date or is not cured by Prometheus\nwithin twenty business days following Merck\u2019s delivery of written notice to the Company of such breach, failure to perform or\ninaccuracy, except that Merck will not have the right to terminate the Merger Agreement as described in this bullet if Merck or Merger\nSub are in breach of the Merger Agreement, such that Prometheus has the right to terminate the Merger Agreement pursuant to the\nterms thereof\u037e or\n \n\u2022\na Company Board Recommendation Change occurs or a tender or exchange offer constituting an Acquisition Proposal has been\npublicly commenced by a person who is not an affiliate or representative of Merck and Prometheus fails to publicly reaffirm the\nCompany Board Recommendation within ten business days following the receipt of a written request from Merck to do so.\n \n\u2022\nby Prometheus, if:\n \n\u2022\nMerck or Merger Sub breaches or fails to perform any of their respective covenants and agreements, or other obligations under the\nMerger Agreement, or any of the representations or warranties set forth in the Merger Agreement become inaccurate, individually or\nin the aggregate with other such breaches, failures to perform or inaccuracies, such that they would reasonably be expected to\nprevent, materially impede or materially delay the ability of Merck or Merger Sub to consummate the transactions contemplated by the\nMerger Agreement (including the Merger), and such breach, failure to perform or inaccuracy of Merck and/or Merger Sub is not\ncapable of being cured by the Termination Date or is not cured within twenty business days following Prometheus\u2019\n \n99\nTable of Contents\ndelivery of written notice to Merck of such breach, failure to perform or inaccuracy, except that Prometheus will not have the right to\nterminate the Merger Agreement as described in this bullet if Prometheus is in breach of the Merger Agreement, such that Merck has\nthe right to terminate the Merger Agreement pursuant to the terms thereof\u037e or\n \n\u2022\nat any time prior to obtaining the Prometheus Stockholder Approval, Prometheus accepts a Superior Proposal and enters into,\nsubstantially concurrently with such termination, a definitive agreement with respect to such Superior Proposal, except that the right\nto terminate the Merger Agreement as described in this bullet is only available if (i) Prometheus has materially complied with its\nobligations related to non-solicitation and as more fully described under \u201cThe Merger Agreement\u2014Other Covenants and Agreements\n\u2014No Solicitation\u037e Prometheus Acquisition Proposals\u037e Company Board Recommendation Change\u201d beginning on page 90 of this\nproxy statement and (ii) Prometheus pays to Merck the termination fee as more fully described under \u201cThe Merger Agreement\u2014",
            "Termination Fee\u037e Certain Expenses\nPrometheus must pay to Merck the Prometheus Termination Fee by wire transfer of immediately available funds to an account or accounts\ndesignated in writing by Merck in the event that the Merger Agreement is terminated:\n \n\u2022\nby either Prometheus or Merck because (i) the Merger has not been consummated by the Termination Date or (ii) the Prometheus\nStockholder Approval has not been obtained upon a vote taken at the Special Meeting (including any adjournment or postponement\nthereof), and in each case:\n \n\u2022\nfollowing the execution and delivery of the Merger Agreement and prior to the Special Meeting, an Acquisition Proposal had been\npublicly announced or had otherwise become publicly disclosed\u037e and\n \n\u2022\nwithin twelve months after such termination, (1) Prometheus enters into a definitive agreement with any third party with respect to\nany Acquisition Proposal or (2) any Acquisition Proposal is consummated (provided that for purposes of this provision, each\nreference to \u201ctwenty-five percent (25%)\u201d and \u201cseventy-five percent (75%)\u201d in the definition of Acquisition Proposal is a reference to\n\u201c50%\u201d)\u037e\n \n\u2022\nby Prometheus at any time prior to obtaining the Prometheus Stockholder Approval, in order to accept a Superior Proposal and enter into,\nsubstantially concurrently with such termination, a definitive agreement with respect to such Superior Proposal\u037e or\n \n\u2022\nby Merck if a Company Board Recommendation Change occurred or a tender or exchange offer constituting an Acquisition Proposal was\npublicly commenced by a person who is not an affiliate or representative of Merck and Prometheus failed to publicly reaffirm the Company\nBoard Recommendation within 10 business days following the receipt of a written request from Merck to do so.\nMerck must pay to Prometheus the Merck Termination Fee by wire transfer of immediately available funds to an account or accounts designed in\nwriting by Prometheus in the event that:\n \n\u2022\nthe Merger Agreement is terminated:\n \n\u2022\nby Prometheus because (x) the Merger has not been consummated by the Termination Date or (y) any order or law permanently\nrestraining, enjoining, preventing or otherwise prohibiting or making illegal prior to the Effective Time the consummation of the\ntransactions contemplated by the Merger Agreement becomes final and non-appealable\u037e\n \n100Table of Contents\n\u2022\nby Merck because the Merger has not been consummated by the Termination Date at a time when the Merger Agreement was\nterminable by Prometheus for the same reason\u037e or\n \n\u2022\nby Merck because any order or law permanently restraining, enjoining, preventing or otherwise prohibiting or making illegal prior to\nthe Effective Time consummation of the transactions contemplated by the Merger Agreement becomes final and non-appealable at a\ntime when the Merger Agreement was terminable by Prometheus for the same reason\u037e and\n \n\u2022\nat the time of such termination, all mutual conditions to the closing of the Merger and all conditions to the closing of the Merger required to\nbe satisfied by Prometheus have been satisfied (or, if any such conditions are by their nature to be satisfied at the closing of the Merger,\nwould have been capable of being satisfied on the date of such termination) or waived other than (i) the expiration or termination of any\napplicable waiting period under the HSR Act and the receipt of all other waivers, approvals and waiting periods under certain other antitrust\nlaws or (ii) the effectiveness, as of immediately prior to the Effective Time, of (x) any law making the Merger or the acquisition of shares of\nPrometheus by Merck or Merger Sub illegal or which has the effect of prohibiting or otherwise preventing the consummation of the\nacquisition of shares of Prometheus by Merck or Merger Sub or the Merger or (y) any order which has the effect of making the Merger\nillegal in the United States or any relevant jurisdiction which has the effect of prohibiting or otherwise preventing the consummation of the\nMerger, solely to the extent that such law or order arises under the HSR Act or any antitrust laws.\nIn no event shall either party be required to pay the Prometheus Termination Fee or the Merck Termination Fee, as applicable, on more than one\noccasion, whether or not the applicable termination fee would be payable under more than one provision of the Merger Agreement at the same or at\ndifferent times.\nThe Merger Agreement further provides that in the event Prometheus or Merck fails to pay any termination fee that becomes due pursuant to, and\nwithin the time frame provided in, the Merger Agreement, and Prometheus or Merck commences a legal proceeding resulting in a judgment against\nPrometheus or Merck, as applicable, for any portion of the fees or expenses due, Prometheus or Merck, as applicable, will be required to pay to\nPrometheus or Merck, as applicable, its reasonable and documented costs and expenses (including reasonable and documented attorneys\u2019 fees) in\nprosecuting such legal proceeding, together with interest on the amount of the applicable termination fee for the date such payment was required to be\nmade until the date that payment was actually received.\nOther than in the case or fraud or a willful breach of the Merger Agreement, any termination fee payable by Prometheus or Merck will be the sole\nand exclusive remedy of Prometheus, Merck, and Merger Sub, and their related parties, as applicable. In the event Merck receives the Prometheus\nTermination Fee in circumstances in which it is payable by Prometheus, Prometheus will have no further liability to Merck or Merger Sub under the\nMerger Agreement except in certain limited circumstances. Similarly, if Prometheus receives the Merck Termination Fee in circumstances in which it is\npayable by Merck, Merck will have no further liability to Prometheus under the Merger Agreement except in certain limited circumstances.",
            "9.7 Severability. In the event that any term or other provision of this Agreement, or the application thereof, is invalid, illegal or incapable of being\nenforced by any rule of Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so\nlong as the economic or legal substance of the Merger is not affected in any manner materially adverse to any party. Upon such determination that any\nterm or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to\neffect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the Merger be effected as originally\ncontemplated to the fullest extent possible.\n9.8",
            "8.3 Fees and Expenses.\n(a) General. Except as set forth in this Section 8.3, all fees and expenses incurred in connection with this Agreement and the transactions\ncontemplated hereby shall be paid by the party or parties, as applicable, incurring such expenses whether or not the Merger are consummated.\n(b) Transfer Taxes. Except as expressly provided in Section 2.8(d), all transfer, documentary, sales, use, stamp, registration, value-added and\nother similar Taxes and fees (the \u201cTransfer Taxes\u201d) incurred in connection with the transaction contemplated by this Agreement and the transactions\ncontemplated hereby shall be paid by Parent and Merger Sub when due. Parent and Merger Sub shall prepare and file, at their expense, all Tax Returns\nand other documentation with respect to such Transfer Taxes.\n(c) Company Termination Fee. The Company shall pay to Parent $ 325,364,166 (the \u201cCompany Termination Fee\u201d), by wire transfer of\nimmediately available funds to an account or accounts designated in writing by Parent, in the event that:\n(i) (A) this Agreement is terminated by Parent or the Company pursuant to Section 8.1(b)(i) or pursuant to Section 8.1(b)(iii)\u037e (B)\nfollowing the execution and delivery of this Agreement and prior to the\n \nA-54Table of Contents\nStockholder Meeting, an Acquisition Proposal (whether or not conditional and whether or not withdrawn) shall have been publicly announced or\nshall have become publicly disclosed\u037e and (C) within twelve (12) months following such termination of this Agreement, (x) the Company enters into\na definitive agreement with any third party with respect to an Acquisition Proposal or (y) an Acquisition Proposal is consummated, in which case\nthe Company Termination Fee shall be payable concurrently with or prior to the Company\u2019s entry into a definitive agreement with respect to such\nAcquisition Proposal\u037e\n(ii) this Agreement is terminated by the Company pursuant to Section 8.1(c)(ii), in which case the Company Termination Fee shall be\npayable substantially concurrently with such termination\u037e or\n(iii) this Agreement is terminated by Parent pursuant to Section 8.1(d)(ii), in which case the Company Termination Fee shall be\npayable within two (2) Business Days after such termination.\nFor purposes of the references to an \u201cAcquisition Proposal\u201d or an \u201cAcquisition Transaction\u201d in Section 8.3(c)(i), all references in the definition of\n\u201cAcquisition Transaction\u201d to \u201ctwenty-five percent (25%)\u201d and \u201cseventy-five percent (75%)\u201d shall each be deemed to be references to \u201cfifty percent\n(50%).\u201d\n(d) Parent Termination Fee. Parent shall pay to the Company $650,728,333 (the \u201cParent Termination Fee\u201d), by wire transfer of immediately\navailable funds to an account or accounts designed in writing by the Company, in the event that:\n(i) (A) the Company terminates this Agreement pursuant to Section 8.1(b)(i) or Section 8.1(b)(ii), (B) Parent terminates this Agreement\npursuant to Section 8.1(b)(i) at a time when the Agreement is terminable by the Company pursuant to Section 8.1(b)(i), or (C) Parent terminates this\nAgreement pursuant to Section 8.1(b)(ii) at a time when the Agreement is terminable by the Company pursuant to Section 8.1(b)(ii)\u037e and\n(ii) at the time of such termination, all of the conditions set forth in Section 7.1 and Section 7.2 have been satisfied (or, if any such\nconditions are by their nature to be satisfied at the Closing, would have been capable of being satisfied on the date of such termination) or waived other\nthan the conditions set forth in Section 7.1(b) or Section 7.1(c) (with respect to Section 7.1(c), solely to the extent that such Law or Order arises under the\nHSR Act or any Antitrust Laws)\u037e\nthen Parent shall pay or cause to be paid to the Company the Parent Termination Fee no later than two (2) Business Days after such termination in the\nevent of a termination by the Company and as a condition to termination in the event of a termination by Parent.\n(e) Single Payment Only. Notwithstanding anything in this Agreement to the contrary, the parties hereto acknowledge and hereby agree\nthat in no event shall either party be required to pay the Company Termination Fee or the Parent Termination Fee, as applicable, on more than one (1)\noccasion, whether or not the Company Termination Fee or Parent Termination Fee, as applicable, may be payable under more than one provision of this\nAgreement at the same or at different times and the occurrence of different events.\n(f) Termination Fee as Exclusive Remedy. The parties acknowledge that the agreements contained in Section 8.3(c) and Section 8.3(d) are an\nintegral part of the transactions contemplated by this Agreement and constitute liquidated damages and not a penalty, and that, without these\nagreements, the parties would not enter into this Agreement. Notwithstanding anything in this Agreement to the contrary, in the event the Agreement is\nterminated under the circumstances in which the Company Termination Fee or the Parent Termination Fee is paid: (i) (A) the payment by the Company of\nthe Company Termination Fee pursuant to Section 8.3(c) (including, in each case, any additional amount payable pursuant to this Section 8.3(f)) shall be\nthe sole and exclusive remedy of Parent, Merger Sub and each other Parent Related Party and (B) the payment by Parent of the Parent Termination Fee\npursuant to Section 8.3(d) (including, in each case, any additional amount payable pursuant to this Section 8.3(f)) shall be the sole and exclusive remedy\nof the Company and each other Company Related Party, (ii) (A) (x) no Parent Related Party or any other Person shall, and no Parent Related Party or any\n \nA-55\nTable of Contents\nother Person shall be entitled to, bring, threaten, commence, maintain or seek any recovery in connection with (and each Parent Related Party hereby\nirrevocably covenants not to bring, threaten, commence, maintain or seek any recovery in connection with) and (y) no Company Related Party shall have\nany liability for or with respect to, in the case of each of clauses (x) and (y), any action, suit, claim, proceeding, investigation, arbitration or inquiry against\nany Company Related Party arising out of this Agreement, any of the transactions contemplated hereby, any breach of any agreement or covenant or any\ninaccuracy in any representation or warranty set forth in this Agreement, any matters forming the basis for such termination or any loss suffered as a\nresult of the failure of the Merger or any other transactions contemplated hereby to be consummated and (B) (x) no Company Related Party or any other\nPerson shall, and no Company Related Party or any other Person shall be entitled to, bring, threaten, commence, maintain or seek any recovery in\nconnection with (and each Company Related Party hereby irrevocably covenants not to bring, threaten, commence, maintain or seek any recovery in\nconnection with) and (y) no Parent Related Party shall have any liability for or with respect to, in the case of each of clauses (x) and (y), any action, suit,\nclaim, proceeding, investigation, arbitration or inquiry against any Parent Related Party arising out of this Agreement, any of the transactions\ncontemplated hereby, any breach of any agreement or covenant or any inaccuracy in any representation or warranty set forth in this Agreement, any\nmatters forming the basis for such termination or any loss suffered as a result of the failure of the Merger or any other transactions contemplated hereby\nto be consummated. If the Company or Parent fails to timely pay any amount due pursuant to this Section 8.3, and, in order to obtain the payment, Parent\nor the Company, as applicable, commences a Legal Proceeding which results in a judgment against the Company or Parent, as applicable, for the payment\nset forth in this Section 8.3, the Company shall pay Parent or Parent shall pay the Company, as applicable, its reasonable and documented costs and\nexpenses (including reasonable and documented attorneys\u2019 fees) incurred in prosecuting such Legal Proceeding, together with interest on such amount\nat the prime rate as published in The Wall Street Journal in effect on the date such payment was required to be made through the date such payment was\nactually received. Notwithstanding the foregoing, payment of the Company Termination Fee or the Parent Termination Fee will not relieve either party\nfrom liability for any fraud or Willful Breach. Notwithstanding anything in this Agreement to the contrary, (i) in the event this Agreement is terminated by\nthe Company for any reason at a time when Parent would have had the right to terminate this Agreement, Parent shall be entitled to receipt of any\nCompany Termination Fee that would have been (or would have subsequently become) payable had Parent terminated this Agreement at such time and\n(ii) in the event this Agreement is terminated by Parent for any reason at a time when the Company would have had the right to terminate this Agreement,\nthe Company shall be entitled to receipt of any Parent Termination Fee that would have been (or would have subsequently become) payable had the\nCompany terminated this Agreement at such time.\n8.4",
            "9.5 Entire Agreement. This Agreement (including any schedules, annexes and exhibits hereto) and the documents and instruments and other\nagreements among the parties hereto as contemplated by or referred to herein, including the Company Disclosure Letter and the Annexes hereto,\nconstitute the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, both\nwritten and oral, among the parties with respect to the subject matter hereof\u037e provided, however, that the Confidentiality Agreement shall not be\nsuperseded, shall survive any termination of this Agreement and shall continue in full force and effect until the earlier to occur of (a) the Effective Time\nand (b) the date on which the Confidentiality Agreement expires in accordance with its terms or is validly terminated by the parties thereto. EACH PARTY\nHERETO AGREES THAT, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS AGREEMENT, NEITHER PARENT,\nMERGER SUB OR ANY OF THEIR REPRESENTATIVES, ON THE ONE HAND, NOR THE COMPANY OR ANY OF ITS REPRESENTATIVES, ON THE\nOTHER HAND, MAKES ANY REPRESENTATIONS OR WARRANTIES TO THE OTHER, AND EACH PARTY HEREBY DISCLAIMS ANY OTHER\nREPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED (INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS\nFOR A PARTICULAR PURPOSE), OR AS TO THE ACCURACY OR COMPLETENESS OF ANY OTHER INFORMATION, MADE (OR MADE\nAVAILABLE BY) BY ITSELF OR ANY OF ITS REPRESENTATIVES, WITH RESPECT TO, OR IN CONNECTION WITH, THE NEGOTIATION,\nEXECUTION OR DELIVERY OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, NOTWITHSTANDING THE DELIVERY OR\nDISCLOSURE TO THE OTHER OR THE OTHER\u2019S REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION WITH RESPECT TO\nANY ONE OR MORE OF THE FOREGOING.\n9.6",
            "9.1 Survival of Representations, Warranties and Covenants. The representations, warranties and covenants of the Company, Parent and Merger\nSub contained in this Agreement shall terminate at the Effective Time, and only the covenants that by their terms survive the Effective Time or are to be\nperformed (in whole or in part) following the Effective Time shall survive the Effective Time in accordance with their respective terms. Notwithstanding\nanything herein to the contrary, after the Effective Time, neither Parent nor Merger Sub shall be permitted to claim that any breach by the Company of any\nof its covenants or obligations under this Agreement results in a failure of a condition to consummate the Merger or excuses performance by Parent or\nMerger Sub of any of its obligations hereunder (and this Agreement shall not be construed to impose any such conditions or excuse such performance).\n9.2",
            "9.8 Remedies.\n(a) Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and\nnot exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude\nthe exercise of any other remedy.\n(b) The parties hereto hereby agree that irreparable damage would occur in the event that any provision of this Agreement were not\nperformed in accordance with its specific terms or were otherwise breached, and that money damages or other legal remedies would not be an adequate\nremedy for any such damages. Accordingly, the parties hereto acknowledge and hereby agree that in the event of any breach or threatened breach by the\nCompany, on the one hand, or Parent and/or Merger Sub, on the other hand, of any of their respective covenants or obligations set forth in this\nAgreement, the Company, on the one hand, and Parent and Merger Sub, on the other hand, shall be entitled (without proof of actual damages or\notherwise or posting or securing any bond or other security), in addition to any other remedy to which they are entitled to under law or equity, to an\ninjunction or injunctions to prevent or restrain breaches or threatened breaches of this Agreement, by the other (as applicable), and to specifically\nenforce the terms and provisions of this Agreement to prevent breaches or threatened breaches of, or to enforce compliance with, the covenants and\nobligations of the other under this Agreement. The Company, on the one hand, and Parent and Merger Sub, on the other hand, hereby agree not to raise\nany objections to the availability of the equitable remedy of specific performance to prevent or restrain breaches or threatened breaches of this\nAgreement by such party (or parties), and to specifically enforce the terms and provisions of this Agreement to prevent breaches or threatened breaches\nof, or to enforce compliance with, the covenants and obligations of such party (or parties) under this Agreement. Any party\u2019s pursuit of any injunction or\nspecific performance at any time will not be deemed an election of remedies or waiver of the right to pursue any other right or remedy to which such party\nmay be entitled, including the right to pursue remedies for liabilities or damages incurred or suffered by a party in the case of a breach of this Agreement\ninvolving Willful Breach or fraud\u037e provided, however, that in no event shall Parent or Merger Sub be entitled to both the\n \nA-59Table of Contents\npayment of the Company Termination Fee, on the one hand, and either specific performance or any other monetary or other remedies, on the other hand."
        ],
        [
            "Solicitation of Proxies\nThe Board is soliciting your proxy, and we will bear the cost of the solicitation of proxies.\nWe have retained MacKenzie Partners, Inc., a proxy solicitation firm, to solicit proxies in connection with the Special Meeting at a cost of\napproximately $20,000 plus expenses. We will also indemnify the proxy solicitor against losses arising out of its provisions of these services on our\nbehalf. In addition, we may reimburse banks, brokers and other nominees representing beneficial owners of Company Shares for their expenses in\nforwarding soliciting materials to such beneficial owners. Proxies may also be solicited by our directors, officers and employees, personally or by\ntelephone, email, fax, over the Internet or other means of communication. No additional compensation will be paid for such services.",
            "Annex C\nPERSONAL AND CONFIDENTIAL\nApril 15, 2023\nBoard of Directors\nPrometheus Biosciences, Inc.\n3050 Science Park Rd\nSan Diego, CA 92121\nLadies and Gentlemen:\nYou have requested our opinion as to the fairness from a financial point of view to the holders (other than Merck & Co. Inc. (\u201cMerck\u201d) and its affiliates)\nof the outstanding shares of common stock, par value $0.0001 per share (the \u201cShares\u201d), of Prometheus Biosciences, Inc. (the \u201cCompany\u201d) of the $200.00\nin cash per Share to be paid to such holders pursuant to the Agreement and Plan of Merger, dated as of April 15, 2023 (the \u201cAgreement\u201d), by and among\nMerck, Splash Merger Sub, Inc., a wholly owned subsidiary of Merck (\u201cAcquisition Sub\u201d), and the Company.\nGoldman Sachs & Co. LLC and its affiliates are engaged in advisory, underwriting, lending, and financing, principal investing, sales and trading, research,\ninvestment management and other financial and non-financial activities and services for various persons and entities. Goldman Sachs & Co. LLC and its\naffiliates and employees, and funds or other entities they manage or in which they invest or have other economic interests or with which they co-invest,\nmay at any time purchase, sell, hold or vote long or short positions and investments in securities, derivatives, loans, commodities, currencies, credit\ndefault swaps and other financial instruments of the Company, Merck, any of their respective affiliates and third parties, and any of their respective\naffiliates, or any currency or commodity that may be involved in the transactions contemplated by the Agreement (the \u201cTransaction\u201d). We have acted as\nfinancial advisor to the Company in connection with, and have participated in certain of the negotiations leading to, the Transaction. We expect to receive\nfees for our services in connection with the Transaction, the principal portion of which is contingent upon consummation of the Transaction, and the\nCompany has agreed to reimburse certain of our expenses arising, and indemnify us against certain liabilities that may arise, out of our engagement. We\nhave provided certain financial advisory and/or underwriting services to the Company and/or its affiliates from time to time for which Goldman Sachs\nInvestment Banking has received, and may receive, compensation, including having acted as bookrunner to the Company in connection to a follow-on\nequity raise in December 2022. We have also provided certain financial advisory and/or underwriting services to Merck and/or its affiliates from time to\ntime for which Goldman Sachs Investment Banking has received, and may receive, compensation, including having acted as financial advisor to Merck in\nconnection to its acquisition of Acceleron Pharma Inc. in November 2021, as joint bookrunner to Merck with respect to its offering of certain notes in\nDecember 2021, as joint lead arranger and joint bookrunner to Organon & Co., a subsidiary of Merck (\u201cOrganon\u201d), with respect to its offering of certain\nterm loans and other secured and unsecured debt in June 2021, and as letter of credit issuer to Organon in connection to a revolving credit facility in June\n2021. We may also in the future provide financial advisory and/or underwriting services to the Company, Merck and their respective affiliates for which\nGoldman Sachs Investment Banking may receive compensation.\nIn connection with this opinion, we have reviewed, among other things, the Agreement\u037e annual reports to stockholders and Annual Reports on Form 10-\nK of the Company for the two fiscal years ended December 31, 2022\u037e the Company\u2019s Registration Statement on Form S-1, including the prospectus\ncontained therein dated March 11, 2021 relating to the Company\u2019s initial public offering, dated February 19, 2021\u037e certain interim reports to stockholders\nand Quarterly Reports on Form 10-Q of the Company\u037e certain other communications from the Company to its stockholders\u037e certain publicly available\nresearch analyst reports for the Company\u037e and certain internal financial analyses and forecasts for the Company and certain forecasts related to the\nexpected utilization by the Company of certain net operating loss carryforwards and tax credits, in each case, as prepared by the\n \nC-1",
            "Annex B\n \nCenterview Partners LLC\n31 West 52nd Street\nNew York, NY 10019\nApril 15, 2023\nBoard of Directors\nPrometheus Biosciences, Inc.\n3050 Science Park Rd\nSan Diego, CA 92121\nThe Board of Directors:\nYou have requested our opinion as to the fairness, from a financial point of view, to the holders of the outstanding shares of common stock, par\nvalue $0.0001 per share (the \u201cShares\u201d) (other than Excluded Shares, as defined below), of Prometheus Biosciences, Inc., a Delaware corporation (the\n\u201cCompany\u201d), of the $200.00 per Share in cash, without interest, proposed to be paid to such holders pursuant to the Agreement and Plan of Merger\nproposed to be entered into (the \u201cAgreement\u201d) by and among Merck & Co., Inc., a New Jersey corporation (\u201cParent\u201d), Splash Merger Sub, Inc., a\nDelaware corporation and wholly owned subsidiary of Parent (\u201cMerger Sub\u201d), and the Company. The Agreement provides that Merger Sub will be\nmerged with and into the Company (the \u201cMerger\u201d and, collectively with the other transactions contemplated by the Agreement, the \u201cTransaction\u201d), as a\nresult of which the Company will become a wholly owned subsidiary of Parent and each issued and outstanding Share immediately prior to the effective\ntime of the Merger (other than any Shares (i) held by the Company as treasury stock, (ii) owned by Parent or any of its subsidiaries, including Merger\nSub, in each case as of immediately prior to the effective time of the Merger, or (iii) the Dissenting Company Shares (as defined in the Agreement) (the\nShares referred to in clauses (i), (ii) and (iii), together with any Shares held by any affiliate of the Company or Parent, the \u201cExcluded Shares\u201d)) will be\nconverted into the right to receive $200.00 per Share in cash, without interest, (the $200.00 per Share consideration to be paid in the Merger, the\n\u201cConsideration\u201d). The terms and conditions of the Transaction are more fully set forth in the Agreement.\nWe have acted as financial advisor to the Board of Directors of the Company in connection with the Transaction. We will receive a fee for our\nservices in connection with the Transaction, a portion of which is payable upon the earlier to occur of (i) the date on which we advise the Board of\nDirectors of the Company that we are prepared to render this opinion and (ii) the rendering of this opinion and a substantial portion of which is\ncontingent upon the consummation of the Merger. In addition, the Company has agreed to reimburse certain of our expenses arising, and indemnify us\nagainst certain liabilities that may arise, out of our engagement.\nWe are a securities firm engaged directly and through affiliates and related persons in a number of investment banking, financial advisory and\nmerchant banking activities. In the past two years, except for our current engagement, we have not been engaged to provide financial advisory or other\nservices to the Company, and we have not received any compensation from the Company during such period. In the past two years, we have provided\nfinancial advisory services unrelated to the Company, to Parent, including in connection with Parent\u2019s spin-off of Organon & Co. in 2021 and other\nstrategic matters, and we have received compensation from Parent during such period. We may provide financial advisory and other services to or with\nrespect to the Company or Parent or their respective affiliates in the future, for which we may receive compensation. Certain (i) of our and our affiliates\u2019\ndirectors, officers, members and employees, or family members of such persons, (ii) of our affiliates or related investment funds and (iii) investment funds\nor other persons in which any of the foregoing may have financial interests or with which they may co-invest, may at any time acquire, hold, sell or trade,\nin debt, equity and other securities or financial instruments (including derivatives, bank loans or other obligations) of, or investments in, the Company,\nParent, or any of their respective affiliates, or any other party that may be involved in the Transaction.\n \nB-1Table of Contents\nThe Board of Directors\nPrometheus Biosciences, Inc.\n4/15/2023\nPage 2\n \nIn connection with this opinion, we have reviewed, among other things: (i) a draft of the Agreement dated April 15, 2023 (the \u201cDraft Agreement\u201d)\u037e\n(ii) Annual Reports on Form 10-K of the Company for the years ended December 31, 2022 and December 31, 2021\u037e (iii) certain interim reports to\nstockholders and Quarterly Reports on Form 10-Q of the Company\u037e (iv) certain publicly available research analyst reports for the Company\u037e (v) certain\nother communications from the Company to its stockholders\u037e and (vi) certain internal information relating to the business, operations, earnings, cash\nflow, assets, liabilities and prospects of the Company, including certain financial forecasts, analyses and projections relating to the Company prepared by\nmanagement of the Company and furnished to us by the Company for purposes of our analysis (the \u201cForecasts\u201d) (collectively, the \u201cInternal Data\u201d). We\nhave also participated in discussions with members of the senior management and representatives of the Company regarding their assessment of the\nInternal Data. In addition, we reviewed publicly available financial and stock market data for the Company. We also compared certain of the proposed\nfinancial terms of the Transaction with the financial terms, to the extent publicly available, of certain other transactions that we deemed relevant and\nconducted such other financial studies and analyses and took into account such other information as we deemed appropriate.\nWe have assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory,\ntax, accounting and other information supplied to, discussed with, or reviewed by us for purposes of this opinion and have, with your consent, relied\nupon such information as being complete and accurate. In that regard, we have assumed, at your direction, that the Internal Data (including, without\nlimitation, the Forecasts) has been reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of\nthe Company as to the matters covered thereby and we have relied, at your direction, on the Internal Data for purposes of our analysis and this opinion.\nWe express no view or opinion as to the Internal Data or the assumptions on which it is based. In addition, at your direction, we have not made any\nindependent evaluation or appraisal of any of the assets or liabilities (contingent, derivative, off-balance-sheet or otherwise) of the Company and we\nhave not been asked to conduct, and did not conduct, a physical inspection of the properties or assets of the Company. We have assumed, at your\ndirection, that the final executed Agreement will not differ in any respect material to our analysis or this opinion from the Draft Agreement reviewed by us.\nWe have also assumed, at your direction, that the Transaction will be consummated on the terms set forth in the Agreement and in accordance with all\napplicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or\nagreement, the effect of which would be material to our analysis or this opinion and that, in the course of obtaining the necessary governmental,\nregulatory and other approvals, consents, releases and waivers for the Transaction, no delay, limitation, restriction, condition or other change will be\nimposed, the effect of which would be material to our analysis or this opinion. We have not evaluated and do not express any opinion as to the solvency\nor fair value of the Company, or the ability of the Company to pay its obligations when they come due, or as to the impact of the Transaction on such\nmatters, under any state, federal or other laws relating to bankruptcy, insolvency or similar matters. We are not legal, regulatory, tax or accounting\nadvisors, and we express no opinion as to any legal, regulatory, tax or accounting matters.\nWe express no view as to, and our opinion does not address, the Company\u2019s underlying business decision to proceed with or effect the\nTransaction, or the relative merits of the Transaction as compared to any alternative business strategies or transactions that might be available to the\nCompany or in which the Company might engage. This opinion is limited to and addresses only the fairness, from a financial point of view, as of the date\nhereof, to the holders of the Shares (other than Excluded Shares) of the Consideration to be paid to such holders pursuant to the Agreement. We have\nnot been asked to, nor do we express any view on, and our opinion does not address, any other term or aspect of the Agreement or the Transaction,\nincluding, without limitation, the structure or form of the Transaction, or any other agreements or arrangements contemplated by the Agreement or\nentered\n \nB-2\nTable of Contents\nThe Board of Directors\nPrometheus Biosciences, Inc.\n4/15/2023\nPage 3\n \ninto in connection with or otherwise contemplated by the Transaction, including, without limitation, the fairness of the Transaction or any other term or\naspect of the Transaction to, or any consideration to be received in connection therewith by, or the impact of the Transaction on, the holders of any other\nclass of securities, creditors or other constituencies of the Company or any other party. In addition, we express no view or opinion as to the fairness\n(financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or payable to any of the officers, directors or employees\nof the Company or any party, or class of such persons in connection with the Transaction, whether relative to the Consideration to be paid to the holders\nof the Shares pursuant to the Agreement or otherwise. Our opinion is necessarily based on financial, economic, monetary, currency, market and other\nconditions and circumstances as in effect on, and the information made available to us as of, the date hereof, and we do not have any obligation or\nresponsibility to update, revise or reaffirm this opinion based on circumstances, developments or events occurring after the date hereof. Our opinion\ndoes not constitute a recommendation to any stockholder of the Company or any other person as to how such stockholder or other person should vote\nwith respect to the Merger or otherwise act with respect to the Transaction or any other matter.\nOur financial advisory services and the opinion expressed herein are provided for the information and assistance of the Board of Directors of the\nCompany (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transaction. The\nissuance of this opinion was approved by the Centerview Partners LLC Fairness Opinion Committee.\nBased upon and subject to the foregoing, including the various assumptions made, procedures followed, matters considered, and qualifications\nand limitations set forth herein, we are of the opinion, as of the date hereof, that the Consideration to be paid to the holders of Shares (other than\nExcluded Shares) pursuant to the Agreement is fair, from a financial point of view, to such holders.\n \nVery truly yours,\n/s/ CENTERVIEW PARTNERS LLC\nCENTERVIEW PARTNERS LLC\n \nB-3\nTable of Contents\nAnnex C"
        ],
        [
            "9.4 Confidentiality. Parent, Merger Sub and the Company hereby acknowledge that Merck Sharp & Dohme LLC and the Company have previously\nexecuted a Confidentiality Agreement, dated as of December 5, 2022 (as amended, the \u201cConfidentiality Agreement\u201d), which will continue in full force and\neffect in accordance with its terms.",
            "3.18 Data Privacy and Security.\n(a) Since January 1, 2022, (i) the IT Systems have not suffered any material failures and (ii) the Company has implemented commercially\nreasonable administrative and technical safeguards designed to protect the integrity, security and confidentiality of Personal Information stored in the IT\nSystems. Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, to the\n \nA-28Table of Contents\nKnowledge of the Company, since January 1, 2022, there have been no unauthorized intrusions or breaches of the security of the IT Systems.\n(b) The Company is, and since January 1, 2022 has been, in compliance with applicable Data Protection Requirements, except for any\nnoncompliance that would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. Except as would\nnot, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, since January 1, 2022, to the Knowledge of the\nCompany, there have been no breaches, violations, outages or unauthorized uses of or accesses to Personal Information maintained by the Company that\nwould require notification of individuals, law enforcement or any Governmental Authority under any applicable Data Protection Law. Since January 1,\n2022 until the date hereof, the Company has not received written communication or claim from any Governmental Authority that alleges that the Company\nis not in compliance with any Data Protection Laws, and no such claim is pending, except as would not reasonably be expected to be material to the\nCompany.\n3.19",
            "3.17 Intellectual Property.\n(a) Section 3.17(a) of the Company Disclosure Letter sets forth a true and complete list, as of the date hereof, of all material Company\nRegistered Intellectual Property Rights, together with the name of the current owner(s), the applicable jurisdictions and the application or registration\nnumbers. Except as otherwise indicated, the Company is the exclusive owner, a co-owner, or a licensee of all material Company Registered Intellectual\nProperty Rights set forth in Section 3.17(a) of the Company Disclosure Letter, free and clear of any Liens other than Permitted Liens.\n \nA-27Table of Contents\n(b) To the Knowledge of the Company, except as would not, individually or in the aggregate, have a Company Material Adverse Effect,\neach Person who is or was an employee or contractor of the Company and who is or was involved in the creation or development of any material\nIntellectual Property owned (or purported to be owned) by the Company has executed a valid agreement containing an assignment to the Company of\nsuch employee\u2019s or contractor\u2019s rights to such material Intellectual Property.\n(c) To the Knowledge of the Company, all material Company Registered Intellectual Property Rights that have been issued or that have\ncompleted registration are valid and enforceable. Except as would not, individually or in the aggregate, reasonably be expected to have a Company\nMaterial Adverse Effect, since January 1, 2022, the Company has not received written notice from any third party challenging the validity, enforceability\nor ownership of any Company Intellectual Property Rights, nor is the Company currently a party to any proceeding relating to any such challenge, except\nfor office actions and other ex parte proceedings in the ordinary course of prosecuting or maintaining the Company Registered Intellectual Property\nRights.\n(d) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, and to the\nKnowledge of the Company, since January 1, 2022 until the date hereof, the Company has not received any written notice from any third party, and, to the\nKnowledge of Company, there is no other assertion or threat from any third party, that the operation of the business of Company as is currently\nconducted, or the Company Products, infringe or misappropriate the Intellectual Property Rights of any third party. Except as would not, individually or in\nthe aggregate, reasonably be expected to have a Company Material Adverse Effect, to the Knowledge of the Company, neither the Company nor any of\nthe Company Products has infringed upon or misappropriated (or will infringe upon or misappropriate, upon the commercialization or use of any\nCompany Products as such Company Products currently exist), the valid and enforceable Intellectual Property Rights of any third party.\n(e) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (i) the\nCompany has taken reasonable measures to maintain the confidentiality of the trade secrets included in the Company Intellectual Property, and (ii) to the\nKnowledge of the Company, such trade secrets included in the Company Intellectual Property have not been disclosed to any Person except pursuant to\nwritten non-disclosure agreements.\n(f) To the Knowledge of the Company, except for any infringements or misappropriations that would not, individually or in the aggregate,\nreasonably be expected to have a Company Material Adverse Effect, no third party is currently infringing or misappropriating any material Company\nIntellectual Property Rights. Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect,\nthe Company is not currently a party to any proceeding (i) challenging the validity, enforceability or ownership of any third party Intellectual Property\nRights or (ii) asserting that the operation of the business of any third party, or any third party products or services, infringes or misappropriates any\nCompany Intellectual Property Rights.\n(g) To the Knowledge of the Company, except as stated in patents and patent applications of the Company Registered Intellectual Property\nRights that a particular invention was made with government support awarded by a federal agency, and except as would not, individually or in the\naggregate, reasonably be expected to have a Company Material Adverse Effect, no funding of any Governmental Authority was used in the development\nof any Company Intellectual Property.\n3.18"
        ]
    ]
}